Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serostim in HIV-Associated Adipose Redistribution Syndrome (HARS)
NCT00082628Phase 3Completed
- Sponsor
- EMD Serono
- Start
- May 2004
- Primary completion
- Sep 2005
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of somatropin in HIV-associated adipose redistribution syndrome (HARS) (5 arms), sponsored by EMD Serono. Primary endpoint: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at 12 weeks. Started May 2004; status: completed.
02
Drugs
somatropin
03
Conditions
HIV-associated adipose redistribution syndrome (HARS)
Beyond the preview
Go deeper on NCT00082628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082628.